CGC 11093
may prove useful in promoting regression of choroidal neovascularization
Also Known As:
CGC-11093; CGC11093
Networked: 3
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results
Experts
| 1. | Marton, Laurence J:
3 articles
(06/2008 - 11/2006)
|
| 2. | Bush, Dorothy:
1 article
(06/2008)
|
| 3. | Carew, Jennifer S:
1 article
(06/2008)
|
| 4. | Casero, Robert A:
1 article
(06/2008)
|
| 5. | Cleveland, John L:
1 article
(06/2008)
|
| 6. | Goodwin, Andrew:
1 article
(06/2008)
|
| 7. | Houghton, Janet A:
1 article
(06/2008)
|
| 8. | Nawrocki, Steffan T:
1 article
(06/2008)
|
| 9. | Reddy, Venudhar K:
1 article
(06/2008)
|
| 10. | Rehg, Jerold E:
1 article
(06/2008)
|
Related Diseases
| 1. | Choroidal Neovascularization
|
| 2. | Rupture
|
| 3. | Neoplasms (Cancer)
|
| 4. | Colonic Neoplasms (Colon Cancer)
12/01/2006
- " Pharmacogenomics of the polyamine analog 3,8,13,18-tetraaza-10,11-[(E)-1,2-cyclopropyl]eicosane tetrahydrochloride, CGC-11093, in the colon adenocarcinoma cell line HCT1161." 12/01/2006
- " To begin the identification of those signaling pathways that are involved in differential cellular responses to the synthetic conformationally restricted polyamine analog CGC-11093, we conducted gene expression profiling, proteomic, and genome-wide DNA methylation and histone acetylation analyses of the HCT116 colon adenocarcinoma cell line after treatment with this analog. "
|
|
Related Drugs and Biologics
Related Therapies and Procedures